Network origin in Keiichi Ono first degree
Entity | Entity type | Industry | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 15 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Keiichi Ono via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
RESONA HOLDINGS, INC. | Regional Banks | Director/Board Member | |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Chief Executive Officer Director/Board Member Director/Board Member Director/Board Member | |
Resona Bank Ltd.
Resona Bank Ltd. Regional BanksFinance Resona Bank, Ltd. provides commercial banking services. It operates through the following segments: Personal, Corporate, and Market. The Personal segment handles financial services for individual customers including personal loans, asset management, and inherited asset consulting. The Corporate segment focuses on lending, asset management that uses trusts, real estate operations, enterprise pensions, and business growth support. The Market segment engages in funds, foreign and local exchanges, bonds, and derivatives. It also offers current and savings accounts, mortgages, debit and credit cards, pension and insurance products, online and phone banking, and investment trusts. The company was founded on May 15, 1918 and is headquartered in Osaka, Japan. | Regional Banks | Director/Board Member | |
GURUNAVI, INC. | Internet Software/Services | Director/Board Member | |
Boston Biomedical, Inc.
Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
Tolero Pharmaceuticals, Inc.
Tolero Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Tolero Pharmaceuticals, Inc. manufactures and markets pharmaceutical products. It is a clinical-stage biopharmaceutical company with a single-minded purpose to alleviate human suffering through the development of medicines to treat cancer and other serious human diseases. The company is headquartered in Lehi, UT. | Pharmaceuticals: Other | Director/Board Member | |
ROIVANT SCIENCES LTD. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
TAKEDA PHARMACEUTICAL COMPANY LIMITED | Pharmaceuticals: Major | Corporate Officer/Principal | |
SUMITOMO CHEMICAL CO., LTD. | Chemicals: Specialty | Corporate Officer/Principal | |
LIXIL CORPORATION | Building Products | Director/Board Member | |
ANGES, INC. | Pharmaceuticals: Generic | Director/Board Member | |
University of Tokyo | College/University | Graduate Degree Undergraduate Degree | |
Pharmaceutical Research & Manufacturers of America
Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Pharmaceuticals: Major | Director/Board Member | |
Hiroshima University | College/University | Doctorate Degree | |
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Pharmaceuticals: Major | President | |
Nihon Medi-Physics Co., Ltd.
Nihon Medi-Physics Co., Ltd. Pharmaceuticals: MajorHealth Technology Nihon Medi-Physics Co., Ltd. is a leading manufacturer of radiopharmaceuticals, based in Japan. The Japanese company is engaged in ensuring stable supply and research and development of new products. It is also working on research and development of "theranostics," a novel medical technology to provide optimal medical service to each patient, as well as on the dissemination of nuclear medicine in Asian countries by licensing its products. Nihon Medi-Physics Co. was founded in 1973, and the CEO is Nobuhiko Tamura. | Pharmaceuticals: Major | Chief Executive Officer | |
National Police Agency | General Government | Director/Board Member | |
Financial Services Agency | General Government | Corporate Officer/Principal | |
Sumitomo Pharma Animal Health Co., Ltd.
Sumitomo Pharma Animal Health Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Sumitomo Pharma Animal Health Co., Ltd. is a Japanese company that manufactures and supplies pharmaceuticals, food ingredients, food additives, veterinary medicines, and diagnostics. The company is based in Osaka, Japan and was founded in 2010. | Pharmaceuticals: Major | Chief Executive Officer | |
Sunovion Pharmaceuticals Europe Ltd.
Sunovion Pharmaceuticals Europe Ltd. Pharmaceuticals: MajorHealth Technology Sunovion Pharmaceuticals Europe Ltd. is a British European pharmaceutical company founded in 2013 that is dedicated to improving the lives of patients through the supply of essential medicines. The company is based in London, UK. The company commercializes and distributes a portfolio of specialty brands and hospital products in 40 countries worldwide, both directly and through strategic partnerships. The company's vision is to become a recognized partner of choice through their commercial excellence, patient focus, and presence across the globe. Sunovion Pharmaceuticals Europe aims to have a positive impact on society through their pioneering focus on their environment, social, and governance (ESG) goals. | Pharmaceuticals: Major | Chief Executive Officer | |
Meltin MMI KK
Meltin MMI KK Medical SpecialtiesHealth Technology Meltin MMI KK develops bio-signal interface technologies. It offers biosignal processing and cable-driven ststems. The company was founded by Sumio Ito, Masahoro Kasuya and Tatsuya Seki and is headquartered in Tokyo, Japan. | Medical Specialties | Director/Board Member | |
MYOVANT SCIENCES LTD. | Biotechnology | Director/Board Member Director/Board Member | |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Pharmaceuticals: Major | Director/Board Member | |
UROVANT SCIENCES LTD. | Pharmaceuticals: Major | Director/Board Member | |
Altavant Sciences, Inc.
Altavant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Altavant Sciences, Inc. is a clinical stage biopharmaceutical company, which provides therapies that treat respiratory diseases with an initial therapeutic focus in pulmonary arterial hypertension (PAH). The company is headquartered in Cary, NC. | Pharmaceuticals: Major | Director/Board Member | |
Sumitovant Biopharma, Inc.
Sumitovant Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Sumitovant Biopharma, Inc. provides biotechnology services. It offers oncology, gene therapy, rare, pulmonary, urological disease, digital innovation and novel platforms. The company is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member |
Statistics
International
Japan | 17 |
United States | 10 |
United Kingdom | 4 |
Bermuda | 2 |
Sectoral
Health Technology | 18 |
Finance | 4 |
Consumer Services | 3 |
Government | 3 |
Technology Services | 2 |
Operational
Director/Board Member | 41 |
Corporate Officer/Principal | 17 |
President | 7 |
Chief Executive Officer | 7 |
Independent Dir/Board Member | 6 |
Most connected contacts
- Stock Market
- Insiders
- Keiichi Ono
- Company connections